Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ERN1 | O75460 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999504 | 0.95 | MAPT (0.49) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL29502289 | 0.95 | MAPT (0.49) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL30412897 | 0.86 | ALDH1A1 (0.55) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL1094404 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL2721914 | 0.81 | ALDH1A1 (0.53) | ALDH1A1MAPTCYP3A4KDM4EALOX15 | |
| SCHEMBL7335 | 0.80 | ATM (0.55) | ALDH1A1MAPTCYP3A4ATMTDP1 | |
| SCHEMBL29663529 | 0.80 | ATM (0.55) | ALDH1A1MAPTCYP3A4ATMTDP1 | |
| SCHEMBL30598678 | 0.80 | MAPT (0.53) | ALDH1A1MAPTCYP3A4ALOX15ATM | |
| SCHEMBL4397890 | 0.80 | MAPT (0.53) | ALDH1A1MAPTCYP3A4ALOX15ATM | |
| SCHEMBL17785642 | 0.80 | ERN1 (0.47) | ALDH1A1MAPTCYP3A4KDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085233-A1 | NOVEL DERIVATIVES OF QUINOLINONES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-119101045-A | Nitrogen-containing heterocyclic compounds, and preparation method and application thereof | 上海宇道生物技术有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-14 | — | — | US | disclosed |
| EP-4240363-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | Merck Sharp & Dohme LLC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-11583524-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-21 | — | — | US | disclosed |
| WO-2022098806-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME CORP. (US) | 2022-05-12 | — | — | WO | disclosed |
| EP-3453707-B1 | BENZAZEPINE DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
| CN-107344931-B | Benzazepine derivative, preparation method thereof, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2020-09-15 | — | — | CN | disclosed |
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20200121667-A1 | Inhibitors Of The Interaction Between MDM2 And P53 | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-23 | — | — | US | disclosed |
| US-20100105668-A1 | Quinazoline derivatives | FREYNE EDDY JEAN EDGARD | 2010-04-29 | — | — | US | disclosed |
| US-7648975-B2 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-19 | — | — | US | disclosed |
| WO-2009037308-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-26 | — | — | WO | disclosed |
| CN-101072781-A | Macrocyclic quinazoline derivatives and their use as mtki | JANSSEN PHARMACEUTICA NV (BE) | 2007-11-14 | — | — | CN | disclosed |
| EP-1828201-A2 | MACROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | US | disclosed |
| CN-1794996-A | Macrocyclic quinazoline derivatives as antiproliferative agents | JANSSEN PHARMACEUTICA NV (BE) | 2006-06-28 | — | — | CN | disclosed |
| WO-2006061417-A2 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-15 | — | — | WO | disclosed |
| EP-1633365-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105765-A1 | MACROCYCLIC QUINAZOLINE DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247237-A1 | Macrocyclic quinazoline derivatives as antiproliferative agents | NR1H3, NR1H2, NCOA3 | ALDH1A1 2648/4885MAPT 4756/4885CYP3A4 112/4885 |
| US-11583524-B2 | Inhibitors of the interaction between MDM2 and P53 | TP53, MDM2, TP53BP1 | ALDH1A1 4139/4885MAPT 1187/4885CYP3A4 2407/4885 |
| US-20200121667-A1 | Inhibitors Of The Interaction Between MDM2 And P53 | TP53, MDM2, TP53BP1 | ALDH1A1 4081/4885MAPT 1012/4885CYP3A4 2388/4885 |
| US-20100105668-A1 | Quinazoline derivatives | NR1H2, NR1H3, NR3C2 | ALDH1A1 2784/4885MAPT 4779/4885CYP3A4 125/4885 |
| US-10669252-B2 | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | TLR8, TLR1, TLR5 | ALDH1A1 2837/4885MAPT 4056/4885CYP3A4 582/4885 |
| US-20230399341-A1 | 7-PHENYL SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | PHKG1, PDXK, HIPK1 | ALDH1A1 2444/4885MAPT 4119/4885CYP3A4 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.